查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2022-2029 年免疫检查点抑製剂的全球市场
市场调查报告书
商品编码
1153824

2022-2029 年免疫检查点抑製剂的全球市场

Global Immune Checkpoint Inhibitors Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

全球免疫检查点抑製剂市场预计在2021年达到311.5029亿美元，2029年达到1324.2741亿美元，预测期内（2022-2029年）的复合年增长率为14.58%。

免疫检查点抑製剂是由抗体製成的药物，可释放免疫系统对癌细胞的攻击。检查点抑製剂旨在克服癌症对免疫系统攻击的主要防御之一。检查点抑製剂阻断癌细胞中的正常蛋白质和 T 细胞中的蛋白质。结果，阻止 T 细胞识别癌细胞的眼罩被移除，导致免疫系统攻击癌细胞。

市场动态

对这些免疫检查点抑製剂的需求不断增长、临床试验的良好结果、研发支出的增加以及新产品推出的增加预计将推动市场增长。

新产品的推出和对免疫检查点抑製剂设备的需求增加将推动市场增长。

全球免疫检查点抑製剂市场的推动因素包括：医疗保健行业对免疫检查点抑製剂的需求激增、产品发布不断增加、临床试验取得良好结果以及患者数量比单独使用传统化疗更多。优势在于主要因素。各种处于临床阶段的药物在治疗各种癌症方面都显示出了良好的效果。例如，2021 年 10 月，阿斯利康的 HIMALAYA III 期试验报告了高水平的有利结果。对于未接受全身治疗的无法切除的肝细胞癌患者，与索拉非尼相比，单剂量 tremelimumab 联合 Imfinzi 可显着改善总生存期。这种新的给药方案被称为 STRIDE 方案。

随着各种最先进的技术进步，免疫检查点抑製剂药物正在兴起，需求也在增加。例如，2022年6月，罗氏宣布Tecentriq（atezolizumab）获欧盟委员会批准用于治疗非小细胞肺癌。 Tecentriq 是针对 PD-L1 >50% 且复发风险高的非小细胞肺癌患者进行完全切除和铂类化疗后的辅助治疗。

与免疫检查点抑製剂治疗相关的高成本阻碍了市场增长。

与检查点抑製剂相关的高昂治疗费用将抑制市场增长。根据 2021 年 12 月发表的《临床路径杂誌》报告“在一线非小细胞肺癌中延长使用免疫检查点抑製剂的成本”，免疫检查点抑製剂的平均成本约为 148,431 美元。美元（约1000 万日元）。 nivolumab/ipilimumab 的成本约为 544,696 美元。

COVID-19 影响分析

疫情对全球金融预期、运营和危机应对策略产生了负面影响。市场进入者正在通过利用研究市场和创造尖端项目来对抗这种流行病，从而改变他们的长期和短期增长战略。即使 COVID-19 损害了行业，重要的是要为您的业务运营製定并儘快制定备份计划。世界各地正在进行各种合作和合併，推动了市场的增长。例如，2022 年 1 月，阿斯利康 (AstraZeneca) 将与 Scorpion Therapeutics 合作，研究、开发和商业化针对难以靶向的癌症蛋白的精准药物，这可能会改变癌症治疗。

内容

第 1 章市场研究方法和范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第四章市场动态

  • 市场影响因素
    • 司机
      • 新产品发布次数增加
      • 对免疫检查点抑製剂的需求不断增长
    • 约束因素
      • 与抑製剂相关的高成本
    • 商机
    • 影响分析

第五章行业分析

  • 搬运工的五种力量
  • 未满足的需求
  • 供应链分析
  • 监管分析

第 6 章 COVID-19 分析

  • COVID-19 市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章药物类别

  • 程序性死亡受体 1 抑製剂 (PD-1)
    • 派姆单抗
    • Cemiplimab
    • 纳武单抗
    • 其他
  • 程序性死亡配体 1 抑製剂 (PDL-1)
    • Avelumab
    • 阿特珠单抗
    • 度伐单抗
  • 细胞毒性 T 淋巴细胞抗原 4 抑製剂 (CTLA-4)
    • 易普利姆玛
  • 淋巴细胞活化基因 3 抑製剂 (LAG-3)
    • Leratolimab

第八章应用

  • 肺癌
  • 血癌
  • 膀胱癌
  • 霍奇金淋巴瘤
  • 黑色素瘤
  • 乳腺癌
  • 宫颈癌
  • 其他

第 9 章分销渠道

  • 医院药房
  • 零售药房
  • 在线药店

第10章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第11章竞争格局

  • 主要发展和战略
  • 公司股票分析
  • 产品基准
  • 值得关注的主要公司名单

第12章公司简介

  • AstraZeneca PLC
    • 公司简介
    • 产品组合和说明
    • 主要亮点
    • 财务摘要
  • Bristol-Myers Squibb
  • Roche Holdings AG
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Merck & Co., Inc
  • Ono Pharmaceutical Co.
  • Kite Pharma, Inc（Gilead company）
  • F. Hoffmann-La Roche AG

第13章 免疫检查点抑製剂的全球市场-DataM

简介目录
Product Code: DMPH867

Market Overview

The global immune checkpoint inhibitors market was valued at US$ 31,150.29 million in 2021 and is estimated to reach US$ 132,427.41 million by 2029, growing at a CAGR of 14.58% during the forecast period (2022-2029).

The immune checkpoint inhibitor is a drug made of antibodies that unleashes an immune system attack on cancer cells. Checkpoint inhibitors seek to overcome one of cancer's primary defenses against an immune system attack. Checkpoint inhibitors block normal proteins in cancer cells or the proteins in T cells. The result is removing the blinders that prevented T cells from recognizing them as cancerous, leading to an immune system assault on them.

Market Dynamics

The increasing demand for these immune checkpoint inhibitors, positive results in clinical trials, the increasing research and development expenditure and growth in novel product launches are expected to drive market growth.

The increasing novel product launches and demand for immune checkpoint inhibitor devices drive market growth.

The global market for immune checkpoint inhibitors is primarily driven by the surge in demand for immune checkpoint inhibitor drugs in the healthcare industry, the rising number of product launches, positive results from clinical trials, and the many advantages over traditional chemotherapy alone. Various drugs in the clinical stage are showing good results in the treatment of various cancers. For instance, in Oct 2021, AstraZeneca' HIMALAYA phase III trial reported positive high-level results. The single dose of tremelimumab and Imfinzi showed a clinically significant overall survival benefit compared with sorafenib for 1st line treatment for unresectable hepatocellular carcinoma patients who haven't gotten systemic therapy. This new dose is known as the STRIDE regimen.

Various latest technological advancements are taking place, and the number of immune checkpoint inhibitors drug launches is increasing, increasing the demand as well. For instance, in Jun 2022, Roche announced the approval of Tecentriq (atezolizumab) for treating non-small cell lung cancer by the European Commission. Tecentriq is an adjuvant treatment that follows full resection and chemotherapy (platinum-based) for non-small cell lung cancer patients with high recurrence risk with PD-L1>50% tumor expression.

High costs associated with immune checkpoint inhibitors therapy will hamper the market's growth.

The high cost of therapies related to checkpoint inhibitors will restrain the market growth. According to the Journal of Clinical Pathways report published in Dec 2021, titled "Cost of extended use of immune checkpoint inhibitors in first-line non-small cell lung cancer," the average cost of immune checkpoint inhibitors is around $148,431. Cost of nivolumab/ipilimumab were around $544,696.

COVID-19 Impact Analysis

The pandemic has negatively impacted global financial expectations, operations and crisis response strategy. Market participants are changing their long-term and short-term growth strategies by utilizing the research market and creating cutting-edge items to combat the pandemic. Even though COVID-19 harms the industry, preparing and implementing backup plans as soon as possible for business operations is crucial. Various collaborations and mergers are happening worldwide, boosting the market's growth. For instance, in Jan 2022, AstraZeneca collaborated with Scorpion Therapeutics to research, develop and market precision medicines against the hard-to-target cancer proteins, potentially transforming the oncology treatment.

Segment Analysis

The programmed death receptor 1 inhibitor (PD-1) drug segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The programmed death receptor 1 inhibitor (PD-1) segment is the highest market holder in the global immune checkpoint inhibitors market. The programmed death receptor 1 inhibitor (PD-1) share accounted for the largest market because of its novel, innovative drug launches, an increasing number of pipelines and increasing prevalence of cancer. PD-1 is a checkpoint protein on the T cells (immune cells), which plays the role of an "off switch" that prevents T cells from attacking the body's other cells. It controls it at the time of its attachment with PD-L1, a kind of protein on a few normal and cancerous cells. When the binding occurs, the T-cell gets the message not to kill the cell. Few cancerous cells have a huge amount of PD-L1, which helps them to hide from immune attacks easily. The monoclonal antibodies targeting PD-1 inhibit the binding of PD-1 with PD-L1, ultimately increasing the immune response against cancerous cells. According to the WHO report 2022, cancer caused approximately ten million deaths globally, making it the major cause globally in 2020. The most common reason for cancer death was lung cancer accounting for around 1.80 million deaths. The novel development of these PD-1 inhibitors will benefit various cancer treatments. Increasing regulatory approvals of these PD-1 inhibitors are increasing market growth. For instance, in Aug 2021, GlaxoSmith Kline announced the approval of Jemparli (dostarlimab), a PD-1 immune checkpoint inhibitor for patients with advanced endometrial cancer and mismatch repair deficient recurrence.

Geographical Analysis

North America holds the largest market share of the global immune checkpoint inhibitors market.

North America dominates the global immune checkpoint inhibitors market, primarily attributed to the increasing number of partnerships or collaborations between companies, the rising demand for immune checkpoint inhibitor drugs, and novel studies. Furthermore, factors including growing expenditure on research and development and the increasing incidence of cancer will likely enhance the growth of the region's immune checkpoint inhibitors market.

Moreover, the growing number of product launches is responsible for the market's growth. Other factors, such as the high spending of GDP on healthcare, stimulate the market's growth. Many key developments are taking place based in this region. For instance, in Sep 2022, AstraZeneca announced the approval of Imfinzi (durvalumab) by the United States Food and Drug Administration for treating metastatic or locally advanced biliary tract cancer patients with chemotherapy. This approval was based on a phase III trial of TOPAZ-1, where Imfinzi and chemotherapy minimized the death risk by 20% compared to chemotherapy alone.

Competitive Landscape

The immune checkpoint inhibitors market is highly competitive with local and global companies. AstraZeneca, Bristol-Myers Squibb, Roche Holdings AG, Novartis AG, Pfizer Inc., Sanofi, Merck & Co., Inc, Key players contributing to the market's growth Ono Pharmaceutical Co., Kite Pharma, Inc (Gilead company), F. Hoffmann-La Roche AG and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth. For instance, in Apr 2020, Kite, Gilead Company and oNKo-innate announced their collaboration for research in cancer immunotherapy. Both companies entered in 2-year collaboration to support the development of next-gen drug therapies and engineered cell therapies focusing on natural killer cells (NK).

AstraZeneca PLC:

Overview:

AstraZeneca is a science-led, bio-pharmaceutical company that researches, develops and markets prescription medicines. It was established in 1999 and is headquartered in Cambridge, United Kingdom.

Product Portfolio:

Imfinzi (Durvalumab): This is an immune checkpoint inhibitor, a human immunoglobulin G1 monoclonal antibody used as immunotherapy for certain cancers. It inhibits the interaction between programmed cell death ligand 1 with programmed death receptor 1.

Key Development: In Aug 2022, AstraZeneca announced that it had completely acquired TeneoTwo Inc. This acquisition includes TeneoTwo's TNB-486, evaluated in B-cell non-Hodgkin lymphoma, phase I clinical stage CD19/CD3 T-cell engager.

The global immune checkpoint inhibitors market report would provide access to approximately 40+ market data tables, 45+ figures, and 200 (approximate) pages.

Table of Contents

1. Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The rising novel product launches
      • 4.1.1.2. Increasing demand for immune checkpoint inhibitor drugs
    • 4.1.2. Restraints:
      • 4.1.2.1. High cost associated with these inhibitors
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces
  • 5.2. Unmet Needs
  • 5.3. Supply chain Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Drug Class

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 7.1.2. Market Attractiveness Index, By Drug Class
  • 7.2. Programmed Death Receptor 1 Inhibitor (PD-1) *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
    • 7.2.3. Pembrolizumab
    • 7.2.4. Cemiplimab
    • 7.2.5. Nivolumab
    • 7.2.6. Others
  • 7.3. Programmed Death Ligand 1 Inhibitors (PDL-1)
    • 7.3.1. Avelumab
    • 7.3.2. Atezolizumab
    • 7.3.3. Durvalumab
  • 7.4. Cytotoxic T Lymphocyte Antigen 4 Inhibitors (CTLA-4)
    • 7.4.1. Ipilimumab
  • 7.5. Lymphocyte Activation Gene 3 Inhibitors (LAG-3)
    • 7.5.1. Relatlimab

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Lung Cancer *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Blood Cancer
  • 8.4. Bladder Cancer
  • 8.5. Hodgkin Lymphoma
  • 8.6. Melanoma
  • 8.7. Breast Cancer
  • 8.8. Cervical Cancer
  • 8.9. Others

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel
  • 9.2. Hospital Pharmacies *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Retail Pharmacies
  • 9.4. Online Pharmacies

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), Distribution Channel
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), Distribution Channel
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. The U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), Distribution Channel
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), Distribution Channel
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), Distribution Channel
    • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking
  • 11.4. List of Key Companies to Watch

12. Company Profiles

  • 12.1. AstraZeneca PLC
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Bristol-Myers Squibb
  • 12.3. Roche Holdings AG
  • 12.4. Novartis AG
  • 12.5. Pfizer Inc.
  • 12.6. Sanofi
  • 12.7. Merck & Co., Inc
  • 12.8. Ono Pharmaceutical Co.
  • 12.9. Kite Pharma, Inc (Gilead company)
  • 12.10. F. Hoffmann-La Roche AG

LIST NOT EXHAUSTIVE

13. Global Immune Checkpoint Inhibitors Market- DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us